BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cocco S, Piezzo M, Calabrese A, Cianniello D, Caputo R, Lauro VD, Fusco G, Gioia GD, Licenziato M, De Laurentiis M. Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. Int J Mol Sci 2020;21:E4579. [PMID: 32605126 DOI: 10.3390/ijms21134579] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Cocco S, Leone A, Piezzo M, Caputo R, Di Lauro V, Di Rella F, Fusco G, Capozzi M, Gioia GD, Budillon A, De Laurentiis M. Targeting Autophagy in Breast Cancer. Int J Mol Sci 2020;21:E7836. [PMID: 33105796 DOI: 10.3390/ijms21217836] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
2 Santolla MF, Talia M, Maggiolini M. S100A4 Is Involved in Stimulatory Effects Elicited by the FGF2/FGFR1 Signaling Pathway in Triple-Negative Breast Cancer (TNBC) Cells. Int J Mol Sci 2021;22:4720. [PMID: 33946884 DOI: 10.3390/ijms22094720] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Al-Saraireh YM, Alshammari FOFO, Youssef AMM, Al-Tarawneh F, Al-Sarayreh S, Almuhaisen GH, Satari AO, Al-Shuneigat J, Alrawashdeh HM. Cytochrome 4Z1 Expression is Associated with Unfavorable Survival in Triple-Negative Breast Cancers. Breast Cancer (Dove Med Press) 2021;13:565-74. [PMID: 34675653 DOI: 10.2147/BCTT.S329770] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Cozzolino M, Cocco S, Piezzo M, Celia G, Costantini S, Abate V, Capone F, Barberio D, Girelli L, Cavicchiolo E, Ascierto PA, Madonna G, Budillon A, De Laurentiis M. A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. J Clin Med 2021;10:E136. [PMID: 33401546 DOI: 10.3390/jcm10010136] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
5 Enciso-Benavides J, Alfaro L, Castañeda-Altamirano C, Rojas N, González-Cabeza J, Enciso N, Riesco F, Castillo M, Enciso J. Biological characteristics of a sub-population of cancer stem cells from two triple-negative breast tumour cell lines. Heliyon 2021;7:e07273. [PMID: 34235281 DOI: 10.1016/j.heliyon.2021.e07273] [Reference Citation Analysis]
6 Jakabova A, Bielcikova Z, Pospisilova E, Petruzelka L, Blasiak P, Bobek V, Kolostova K. Characterization of circulating tumor cells in early breast cancer patients receiving neoadjuvant chemotherapy. Ther Adv Med Oncol 2021;13:17588359211028492. [PMID: 34345252 DOI: 10.1177/17588359211028492] [Reference Citation Analysis]
7 Malhão F, Ramos AA, Macedo AC, Rocha E. Cytotoxicity of Seaweed Compounds, Alone or Combined to Reference Drugs, against Breast Cell Lines Cultured in 2D and 3D. Toxics 2021;9:24. [PMID: 33572635 DOI: 10.3390/toxics9020024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Han Y, Wang J, Xu B. Novel biomarkers and prediction model for the pathological complete response to neoadjuvant treatment of triple-negative breast cancer. J Cancer 2021;12:936-45. [PMID: 33403050 DOI: 10.7150/jca.52439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Kanwal B. Untangling Triple-Negative Breast Cancer Molecular Peculiarity and Chemo-Resistance: Trailing Towards Marker-Based Targeted Therapies. Cureus 2021;13:e16636. [PMID: 34458041 DOI: 10.7759/cureus.16636] [Reference Citation Analysis]
10 Tian H, Ma D, Tan X, Yan W, Wu X, He C, Zhong L, Zhang Y, Yu B, Zhang Y, Qi X. Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review. Front Pharmacol 2021;12:770663. [PMID: 34938186 DOI: 10.3389/fphar.2021.770663] [Reference Citation Analysis]
11 Wang H, Ma H, Sové RJ, Emens LA, Popel AS. Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer. J Immunother Cancer 2021;9:e002100. [PMID: 33579739 DOI: 10.1136/jitc-2020-002100] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Hall PE, Schmid P. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials. Expert Opin Emerg Drugs 2021;26:131-47. [PMID: 33870839 DOI: 10.1080/14728214.2021.1916468] [Reference Citation Analysis]
13 Sun X, Luo Z, Gong L, Tan X, Chen J, Liang X, Cai M. Identification of significant genes and therapeutic agents for breast cancer by integrated genomics. Bioengineered 2021;12:2140-54. [PMID: 34151730 DOI: 10.1080/21655979.2021.1931642] [Reference Citation Analysis]